- Aflibercept
Drugbox
IUPAC_name = Unable to be assigned
CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=4318 | H=6788 | N=1164 | O=1304 | S=32
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Aflibercept is a
fusion protein under development for the treatment ofcancer .It functions as an inhibitor of
vascular endothelial growth factor .cite journal |author=Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ |title=The Role of Vascular Endothelial Growth Factor and Estradiol in the Regulation of Endometrial Angiogenesis and Cell Proliferation in the Marmoset |journal=Endocrinology |volume= |issue= |pages= |year=2008 |month=May |pmid=18499749 |doi=10.1210/en.2008-0325 |url=http://endo.endojournals.org/cgi/pmidlookup?view=long&pmid=18499749] cite journal |author=Duncan WC, van den Driesche S, Fraser HM |title=Inhibition of Vascular Endothelial Growth Factor in the Primate Ovary Up-Regulates Hypoxia-Inducible Factor-1{alpha} in the Follicle and Corpus Luteum |journal=Endocrinology |volume=149 |issue=7 |pages=3313–20 |year=2008 |month=July |pmid=18388198 |doi=10.1210/en.2007-1649 |url=http://endo.endojournals.org/cgi/pmidlookup?view=long&pmid=18388198]Aflibercept is being co-developed by
Sanofi-Aventis and Regeneron Pharmaceuticals.As of 2008 , it is currently in phase III clinical trials.References
Wikimedia Foundation. 2010.
